Mauna Kea Technologies (LTS:0P5I) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0P5I Mauna Kea Technologies SA LTS:0P5I
46 GF Score
Price €0.15
GF Value €0.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mauna Kea Technologies ROCE %?

Mauna Kea Technologies LTS:0P5I 46 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates LTS:0P5I with a GF Score™ of 46/100 and a GF Value™ of €0.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mauna Kea Technologies's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Mauna Kea Technologies  (LTS:0P5I) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mauna Kea Technologies ROCE % Related Terms

Mauna Kea Technologies ROCE % Historical Data

* Premium members only.

The historical data trend for Mauna Kea Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mauna Kea Technologies ROCE % Chart

Mauna Kea Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -84.51 -89.03 -179.11 0.00 0.00

Mauna Kea Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -567.06 -500.89 0.00 0.00 0.00
LTS:0P5I
46GF Score
Mauna Kea Technologies SA LTS:0P5I
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mauna Kea Technologies ROCE % Calculation

Mauna Kea Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=11.752/( ( (16.245 - 33.367) + (13.407 - 5.324) )/ 2 )
=11.752/( (-17.122+8.083)/ 2 )
=11.752/-4.5195
=-260.03 %

Mauna Kea Technologies's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=31.334/( ( (12.66 - 35.211) + (13.407 - 5.324) )/ 2 )
=31.334/( ( -22.551 + 8.083 )/ 2 )
=31.334/-7.234
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Mauna Kea Technologies (LTS:0P5I) has a ROCE % of 0.00% as of Dec. 2025.
Is Mauna Kea Technologies' ROCE % too high?
Mauna Kea Technologies' current ROCE % is 0.00%. Overall, Mauna Kea Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' ROCE % compare to ABT and SYK?
Mauna Kea Technologies' ROCE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.18, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mauna Kea Technologies's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (LTS:0P5I) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.15 — trading 19.1% above its estimated fair value. The current ROCE % is 0.00%. Mauna Kea Technologies' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Mauna Kea Technologies (LTS:0P5I), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mauna Kea Technologies (LTS:0P5I) Overvalued in 2026?

Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued. The current stock price of €0.15 is trading 19.1% above its estimated GF Value™ of €0.13. GuruFocus considers Mauna Kea Technologies to be Modestly Overvalued.

Key valuation signals for LTS:0P5I:

  • ROCE %: 0.00%
  • GF Value™: €0.13 vs. price of €0.15 (19.1% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the LTS:0P5I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mauna Kea Technologies Business Description

Other Exchanges ALMKT:France1MK:Germany
Address 9 rue d\'Enghien, Paris, FRA, 75010
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
46GF Score

Get the complete analysis for LTS:0P5I

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.13
GF Value